Prognostic impact of changes in aortic stiffness for cardiovascular and mortality outcomes in individuals with type 2 diabetes: the Rio de Janeiro cohort study

Claudia R L Cardoso, Nathalie C Leite and Gil Fernando Salles*

**Abstract**

**Background:** The prognostic importance of changes in aortic stiffness for the occurrence of adverse cardiovascular outcomes and mortality has never been investigated in patients with type 2 diabetes. We aimed to evaluate it in a cohort of 417 patients.

**Methods:** Changes in aortic stiffness were assessed by 2 carotid-femoral pulse wave velocity (CF-PWV) measurements performed over a 4-year period. Multivariable Cox analysis examined the associations between changes in CF-PWV, evaluated as a continuous variable with splines and as categorical ones (quartiles and stable/reduction/increase subgroups), and the occurrence of total cardiovascular events (CVEs), major adverse CVEs (MACEs), and all-cause and cardiovascular mortality.

**Results:** Over a median follow-up of 8.2 years after the 2nd CF-PWV measurement, there were 101 total CVEs (85 MACEs) and 135 all-cause deaths (64 cardiovascular). As a continuous variable, the lowest risk nadir was at -2.5%/year of CF-PWV change, with significantly higher risks of mortality associated with CF-PWV increases, but no excess risks at extremes of CF-PWV reduction. Otherwise, in categorical analyses, patients in the 1st quartile (greatest CF-PWV reductions) had excess risks of all-cause and cardiovascular mortality (hazard ratios [HRs]: 2.0–2.7), whereas patients in 3rd quartile had higher risks of all outcomes (HRs: 2.0–3.2), in relation to the lowest risk 2nd quartile subgroup. Patients in the 4th quartile had higher risks of all-cause mortality. Categorization as stable/reduction/increase subgroups was confirmatory, with higher risks at greater reductions (HRs: 1.7–3.3) and at greater increases in CF-PWV (HRs: 1.9–3.4), in relation to those with stable CF-PWV.

**Conclusions:** Changes in aortic stiffness, mainly increases and possibly also extreme reductions, are predictors of adverse cardiovascular outcomes and mortality in individuals with type 2 diabetes.

**Keywords:** Aortic stiffness, Cardiovascular events, Carotid-femoral pulse wave velocity, Cohort study, Mortality, Type 2 diabetes

**Background**

Individuals with diabetes have greater arterial stiffness [1–3] and higher cardiovascular morbidity and mortality than general populations [4–6]. This higher cardiovascular risk is not completely explained by clustering of traditional risk factors and increased arterial stiffness may...
be one pathophysiological mechanism linking diabetes to increased cardiovascular morbidity and mortality [7]. Increased aortic stiffness, evaluated by its gold-standard carotid-femoral pulse wave velocity (CF-PWV) measurement [8], has been largely associated with adverse cardiovascular events and all-cause mortality in different populations and clinical conditions [8–10], including in diabetes [11, 12]. Because of its prognostic importance, some studies investigated the factors associated with aortic stiffness progression in diverse populations [13–17], including diabetes [18]. Ageing and high blood pressure (BP) are its main determinants, but African ancestry, abdominal obesity, higher heart rate, and worse renal function had also been related to its increase [13–17]. In type 2 diabetic individuals, female gender, higher heart rates, dyslipidemia, the presence of diabetic retinopathy and poorer glycem control were associated with aortic stiffness progression, besides age and systolic BP (SBP) [18]. In this study, it was possible to establish temporal associations between high Hba1c levels and aortic stiffness progression, which might be in part mediated by advanced glycation end-products (AGEs) formation [18].

On the other hand, some studies demonstrated that reducing aortic stiffness (‘de-stiffening’) is feasible [8], by either non-pharmacological interventions, such as weight loss [19] and regular physical activity [20], or by pharmacological interventions such as renin-angiotensin-aldosterone system inhibitors [21], statins [22] and newer antidiabetic drugs [23]. Although an AGE cross-link breaker has been demonstrated to reduce arterial stiffness in short-term use [24], no other study confirmed the potential beneficial effects of any specific anti-AGE or anti-AGE receptor (RAGE) drugs [25].

Nevertheless, as far as we know, no previous study in type 2 diabetes evaluated whether changes in aortic stiffness were predictive of adverse clinical outcomes. Only three previous investigations, two in individuals with end-stage renal failure under hemodialysis (26,27) and one in resistant hypertension (28), showed that aortic stiffness reduction was associated with better cardiovascular outcomes and mortality. Therefore, we aimed to explore if changes in aortic stiffness, assessed by 2 CF-PWV measurements over a 4-year period, were predictors of adverse cardiovascular outcomes and all-cause mortality in a middle-aged to elderly type 2 diabetes cohort, independent of changes in BP, Hba1c and lipid levels.

Methods
Study overview
This was a prospective study nested within the Rio de Janeiro Type 2 Diabetes (RIO-T2D) cohort study with 417 patients with type 2 diabetes who performed a first CF-PWV measurement between 2004 and 2007 and repeated the measurement between 2009 and 2013, and were followed-up until December 2019 in the diabetes outpatient clinic of our tertiary-care University Hospital. All participants gave written informed consent, and the study protocol was approved by the local Ethics Committee. The characteristics of this cohort, the baseline procedures and the diagnostic definitions have been detailed elsewhere [11, 18, 26–28]. In brief, inclusion criteria were all adult type 2 diabetic individual up to 80 years old with either any microvascular (retinopathy, nephropathy or neuropathy) or macrovascular (coronary, cerebrovascular or peripheral artery disease) complication, or with at least two other modifiable cardiovascular risk factors. Exclusion criteria were morbid obesity (BMI ≥ 40 kg/m²), advanced renal failure (serum creatinine >180 μmol/L or estimated glomerular filtration rate <30 ml/min/1.73m²) or the presence of any serious concomitant disease limiting life expectancy. Specifically for this analysis, patients with peripheral arterial disease, defined by an ankle-brachial index <0.9, or with heart failure, either detected at baseline or during the time-interval between the 2 CF-PWV measurements, were also excluded. All patients were submitted to a standard baseline protocol that included a complete clinical examination, laboratory evaluation, and CF-PWV measurement. Diagnostic criteria for diabetic chronic complications were detailed previously [11, 18, 26–28]. Briefly, coronary heart disease was diagnosed by clinical, electrocardiographic criteria, or by positive ischemic stress tests, and cerebrovascular disease was diagnosed by history and physical examination. Diabetic retinopathy was evaluated by an ophthalmologist. The diagnosis of nephropathy needed at least two albuminurias ≥30 mg/24 h or confirmed reduction of glomerular filtration rate (<60 ml/min/1.73m², or serum creatinine >130 μmol/L). Peripheral neuropathy was ascertained by clinical examination (knee and ankle reflex activities, pinprick, temperature and vibration perception using a 128-Hz tuning fork and 10-gr monofilament pressure sensation). Neuropathy was defined as the presence of at least two of the following: symptoms, reduced pinprick, temperature and vibration perception, insensitivity to monofilament, and absent tendon reflexes. Arterial hypertension was diagnosed if mean systolic (SBP) ≥140 mmHg or diastolic BP (DBP) ≥90 mmHg on a mean of 4 BP measurements performed on two occasions at study entry or if anti-hypertensive drugs had been prescribed. For this report, office (clinic) BP was measured in the vascular laboratory immediately before each CF-PWV measurement. It was measured twice in the supine position, after at least 10 min rest, using an automatic oscillometric BP monitor Omron HEM-907 XL (Omron Healthcare, Tokyo, Japan) with a
suitably sized cuff. BP considered was the mean between the two readings. Heart rate was also recorded. Mean arterial pressure (MAP) were calculated as DBP + [(SBP – DBP) / 3]. Annual relative changes in MAP between the 2 CF-PWV measurements were calculated as [[(2nd MAP – 1st MAP) / 1st MAP] * 100] / time-interval between 1st and 2nd measurements (in years). Changes in heart rate were calculated similarly. We also calculated the mean BP between the 2 CF-PWV measurements taking into account not only the 2 BPs before each CF-PWV measurement, but also all the in-between BPs measured during clinical attendances (patients had a median of 4 annual BP measurements). Laboratory evaluation included fasting glycemia, glycated hemoglobin, serum creatinine and lipids. Albuminuria and proteinuria were evaluated in two non-consecutive sterile 24-hour urine collections. We calculated the mean values of these laboratory variables obtained during the time-interval between the 2 CF-PWV measurements (all had at least 2–4 annual laboratory exams, except albuminuria which was performed once a year).

**Carotid-femoral PWV measurement**

All CF-PWV measurements were performed by the same single trained independent observer, unaware of other patients’ data, using the foot-to-foot velocity method with the Complior equipment and software (Artech-Medical, Paris, France), as previously described [11, 18, 26]. Patients were in the supine position after a minimum 10 min rest at a comfortable room temperature, and all examinations were carried out in the morning, between 0900 and 1100 h, after patients had taken their morning dose of antihypertensive and antidiabetic medications. Briefly, waveforms were obtained transcutaneously by mechanotransducers over the right common carotid artery and the right femoral artery simultaneously during a minimum period of 10–15 s. The time delay (Δt) was measured between the troughs of the two waveforms, and the distance (D) covered by the waves was measured directly between the femoral and the carotid recording sites. Direct carotid-femoral distance was corrected by a factor of 0.8, as recommended [29]. CF-PWV was calculated as D (meters)/Δt (seconds). Three consecutive measurements were performed on each occasion and the mean value was used. If one of the measurements differed by >0.5 m/s from the other measurements, it was discarded and further measurements were obtained until there were 3 CF-PWV measurements that differed by ≤ 0.5 m/s. In our laboratory, the intra-observer repeatability of CF-PWV measurement has an intra-class correlation coefficient > 0.90 and a mean relative error < 5% [18]; and the Complior equipment and procedures have been previously validated [30]. We calculated the relative annual CF-PWV changes as \( [(2nd \text{ CF-PWV} - 1st \text{ CF-PWV}) / 1st \text{ CF-PWV}] * 100 \) / time-interval between 1st and 2nd measurements (in % per year). CF-PWV changes were analyzed as a continuous variable and divided into quartiles (the 1st quartile with the greatest reductions and the 4th with the greatest increases in CF-PWV). We also dichotomized CF-PWV changes by considering whether CF-PWV persisted stable (relative changes between −1% and +1%/year), reduced (relative change < -1%/year) or increased (relative change > +1%/year).

**Follow-up and endpoints assessment**

The follow-up for this report began after the 2nd CF-PWV measurement. All patients were followed-up regularly with 2–4 annual visits until December 2019 and managed by a standardized protocol according to current guidelines. The observation period was considered as the number of months from the date of 2nd CF-PWV measurement to the date of the last clinical visit in 2019 or the first endpoint, whichever came first. The primary outcomes were the occurrence of any cardiovascular event (CVE) and all-cause mortality. Definitions of endpoints have been previously detailed [11, 27, 28]. Total CVEs included the following: fatal or non-fatal myocardial infarctions (MIs), sudden cardiac deaths, new-onset heart failure, death from progressive heart failure, any myocardial revascularization procedure, fatal or non-fatal strokes, any aortic or lower limb revascularization procedure, any amputation above the ankle, and deaths from aortic or peripheral arterial disease [11, 27, 28]. Secondary outcomes were the classic 3-point major adverse cardiovascular events (MACEs: non-fatal MIs and strokes plus all cardiovascular deaths), and cardiovascular mortality. Outcomes were adjudicated from medical records (most non-fatal and fatal in-hospital events were attended at our hospital), death certificates and interviews with attending physicians and patient families, by a standard questionnaire reviewed by two independent observers [11, 27, 28].

**Statistical analysis**

Continuous data were expressed as means and SD if normally distributed or as medians and interquartile range (IQR) if asymmetrically distributed. In initial exploratory-descriptive analysis, individuals were divided into quartiles of relative CF-PWV changes, and were compared by ANOVA (with post-hoc Bonferroni’s test), Kruskall-Wallis test or \( \chi^2 \) test, when adequate. Kaplan-Meier curves of cumulative endpoints incidence during follow-up, compared by log-rank tests, were performed for estimating different incidences of outcomes between the subgroups described previously. For assessing the independent prognostic value of CF-PWV changes
parameters (continuous relative changes, its quartiles, and categorical subgroups of changes) for each outcome, time-to-event multivariate Cox analyses were undertaken. For patients with multiple events, analyses were restricted to the first event under study. Because there were evidences of non-linear associations between continuous relative CF-PWV changes and the risks of adverse outcomes (the lowest risk subgroup was not the 1st quartile but the 2nd one), we performed an extended Cox analyses with restricted natural cubic splines, which included both linear and non-linear (spline) terms, with four knots located at the 5th, 35th, 65th, and 95th percentile values of relative CF-PWV changes [31–34]. This approach allows the assessment of linear or non-linear associations, both visually and statistically, without assuming any particular functional form/contour [31–34]. In a initial exploratory analysis without defining an a priori reference value (i.e., with floating hazard ratios), it was observed that the lowest risk for all-cause mortality was at the −2.4% value of relative CF-PWC changes and at −2.6% for total CVEs occurrence. Hence, in these Cox analyses with splines, we subsequently defined the reference CF-PWV change value at −2.5%. All Cox models were adjusted for the following covariates: age, sex, first CF-PWV measurement (to account for the dependency of CF-PWV changes on their initial levels and also to control for possible regression to the mean), BMI, diabetes duration, smoking, presence of macro- and microvascular complications at baseline, anti-hypertensive and insulin treatment, mean SBP, HbA1c and LDL-cholesterol levels and changes in MAP and heart rate between the first and second CF-PWV measurements. We also performed specific interaction and sensitivity analyses between CF-PWV changes with age and sex, and after excluding those individuals who died within the first 2 years after the 2nd CF-PWV measurement (to assess possible reverse causality). Results of Cox analyses were presented as adjusted hazards ratios (HRs) with their 95% confidence intervals (CIs); and a 2-tailed probability value < 0.05 was considered significant. Statistics were performed with SPSS version 19.0 (SPSS Inc, Chicago, IL, USA) and R version 3.6.0 (R Foundation for Statistical Computing, Vienna, Austria).

Results
Baseline characteristics and changes in CF-PWV and BPs during the measurement period
Four-hundred and seventeen individuals with T2D performed 2 CF-PWV measurements over a median time-interval of 4.2 years (IQR: 4.0–4.4 years). Mean 1st CF-PWV was 9.7 m/s (SD: 2.0; median: 9.4; IQR: 8.2–10.8 m/s); and mean 2nd CF-PWV was 10.2 m/s (SD: 2.1; median: 9.9; IQR: 8.6–11.6 m/s). There was an overall median absolute CF-PWV increase of 0.1 m/s per year, corresponding to a median relative increase of 1.1% per year. Overall, 84 individuals (20%) persisted with stable CF-PWV (relative change between −1 and +1% per year), 213 (51%) had increased CF-PWV (relative change >1%) and 120 individuals (29%) had reduced CF-PWV (relative change <-1%). Table 1 outlines the baseline characteristics of all evaluated individuals and of those divided into quartiles of relative CF-PWV changes (Q1 greatest reductions; Q4 greatest increases). Patients with the greatest reductions in CF-PWV (Q1) were older and had longer diabetes duration, had a higher prevalence of arterial hypertension and were more frequently treated with ACEi/ARBs and calcium-channel blockers. They had higher BP levels at the 1st CF-PWV measurement but lower BP levels at the 2nd CF-PWV measurement, which meant that they had greater reductions in MAP between CF-PWV measurements. In contrast, individuals with the greatest CF-PWV increases (Q4) had the opposite profile: lower BP levels at the 1st CF-PWV measurement and higher BPs at the 2nd measurement; hence, greater increases in MAP between the 2 CF-PWV measurements. Otherwise, mean BP levels during the whole 4.2 year measurement period, which took into account all office BP measurements performed during this time-interval, were equivalent among quartile subgroups of CF-PWV changes. Additionally, individuals with greatest CF-PWV increases (Q4) had higher mean HbA1c levels than the other subgroups. There were no differences in antidiabetic treatment among the quartile subgroups, only 17 patients were using other antihyperglycemic drugs than metformin, sulphonylureas or insulin, and none of them were using GLP-1 agonists or SGLT-2 inhibitors.

Follow-up and incidence of adverse outcomes
After the CF-PWV measurement period, patients were further followed-up for a median of 8.2 years (IQR: 6.3–9.2 years, maximum 11 years), which corresponded to 3,160 person-years (PY) of follow-up, over which there were 101 total CVEs (incidence rate: 33.6 per 1,000 PY), 85 MACEs (27.8 per 1,000 PY), and 135 all-cause deaths (42.7 per 1,000 PY), 64 from cardiovascular causes. Table 1 (bottom) shows that the incidence rates of all adverse outcomes were lowest in the 2nd quartile subgroup (Q2) and significantly increased in the 1st and 3rd quartile subgroups of CF-PWV changes, which indicated probable non-linear associations between CF-PWV changes and risks of adverse outcomes. The lowest incidence of adverse outcomes in the Q2 subgroup was confirmed in Kaplan-Meier curves shown on Figs. 1 and 2 (upper panels). Figures 1 and 2 (lower panels) also demonstrated that the stable CF-PWV subgroup also had
Table 1  Characteristics of all 417 diabetic patients evaluated and of those divided into quartiles of relative changes in aortic stiffness (Q1, greatest reductions; Q4, greatest increases)

| Characteristics                                      | All patients (n = 417) | Q1 < -1.38% (n = 104) | Q2 -1.38 to +1.10% (n = 104) | Q3 +1.11 to +4.03% (n = 105) | Q4 > +4.03% (n = 104) | p-value |
|------------------------------------------------------|------------------------|-----------------------|-------------------------------|-------------------------------|-----------------------|---------|
| Age (years)                                          | 60.0 (9.0)             | 62.2 (8.7) †          | 58.3 (8.7)                   | 59.9 (8.8)                   | 59.7 (9.4)           | 0.017   |
| Male sex (%)                                         | 35.7                   | 41.3                  | 27.9                         | 44.8 †                       | 28.8                 | 0.018   |
| Body mass index (kg/m²)                              | 29.6 (4.7)             | 29.9 (4.7)            | 30.1 (4.5)                   | 29.1 (4.6)                   | 29.5 (4.9)           | 0.47    |
| Smoking, current/past (%)                            | 42.7                   | 45.2                  | 40.4                         | 39.0                         | 46.2                 | 0.67    |
| Diabetes duration (years)                            | 8 (3–15)               | 9.5 (4–19) †          | 5.5 (2–15)                   | 7 (3–15)                     | 7.5 (3–14)           | 0.064   |
| Chronic diabetic complications (%)                   |                        |                       |                               |                               |                      |         |
| Cerebrovascular disease                              | 8.9                    | 6.7                   | 10.6                         | 10.5                         | 7.7                  | 0.69    |
| Coronary artery disease                              | 18.0                   | 23.1                  | 19.2                         | 13.3                         | 16.3                 | 0.30    |
| Retinopathy                                          | 30.0                   | 36.5                  | 26.0                         | 28.8                         | 28.8                 | 0.38    |
| Nephropathy                                          | 26.9                   | 26.0                  | 27.9                         | 25.7                         | 27.9                 | 0.97    |
| Peripheral neuropathy                                | 26.4                   | 32.7                  | 24.0                         | 23.8                         | 25.0                 | 0.41    |
| Diabetes treatment (%)                               |                        |                       |                               |                               |                      |         |
| Metformin                                            | 88.5                   | 87.5                  | 86.5                         | 90.5                         | 89.4                 | 0.81    |
| Sulfonylureas                                        | 45.3                   | 48.1                  | 40.4                         | 43.8                         | 49.0                 | 0.57    |
| Insulin                                              | 45.8                   | 47.1                  | 40.4                         | 54.3                         | 41.3                 | 0.16    |
| Other medications a                                  | 4.1                    | 3.8                   | 3.8                          | 4.8                          | 3.8                  | 0.93    |
| Dyslipidemia (%)                                     | 88.0                   | 84.6                  | 86.5                         | 90.5                         | 90.4                 | 0.47    |
| Statins use (%)                                      | 75.8                   | 73.1                  | 74.0                         | 76.2                         | 79.8                 | 0.68    |
| Arterial hypertension (%)                            | 85.9                   | 94.2 †                | 80.8                         | 81.0                         | 87.5                 | 0.015   |
| Number of antihypertensive drugs                     | 3 (1–3)                | 3 (2–4)               | 3 (1–4)                      | 2 (1–3)                      | 3 (1–3)              | 0.12    |
| ACE inhibitors / AR blockers (%)                     | 84.1                   | 91.3 †                | 77.9                         | 85.7                         | 81.6                 | 0.050   |
| Diuretics (%)                                        | 67.3                   | 73.1                  | 65.4                         | 61.0                         | 69.9                 | 0.26    |
| Calcium channel blockers (%)                         | 30.8                   | 41.3                  | 30.8                         | 25.7                         | 25.2                 | 0.042   |
| Beta-blockers (%)                                    | 48.8                   | 53.8                  | 48.1                         | 43.8                         | 49.5                 | 0.54    |
| Mean SBP between CF-PWV measurements (mmHg) b         | 139 (16)               | 141 (14)              | 138 (14)                     | 139 (16)                     | 139 (18)             | 0.54    |
Table 1 (continued)

| Characteristics | All patients | Q1 < -1.38% (n = 104) | Q2 -1.38 to +1.10% (n = 104) | Q3 +1.11 to +4.03% (n = 105) | Q4 > +4.03% (n = 104) | p-value |
|-----------------|--------------|------------------------|-----------------------------|-----------------------------|----------------------|---------|
| Mean DBP between CF-PWV measurements (mmHg) | 77 (9) | 77 (8) | 76 (8) | 77 (9) | 78 (9) | 0.69 |
| 1st CF-PWV measurement | | | | | | |
| CF-PWV (m/s) | 9.7 (2.0) | 11.1 (2.3) * | 9.5 (1.8) | 9.5 (1.7) | 8.8 (1.6) ‡ | <0.001 |
| SBP (mmHg) | 147 (23) | 154 (25) ‡ | 147 (21) | 145 (22) | 143 (23) | 0.002 |
| DBP (mmHg) | 80 (12) | 83 (13) | 80 (11) | 78 (12) | 78 (13) | 0.025 |
| Heart rate (bpm) | 72 (12) | 73 (12) | 71 (13) | 72 (12) | 71 (12) | 0.35 |
| 2nd CF-PWV measurement | | | | | | |
| CF-PWV (m/s) | 10.2 (2.1) | 9.5 (2.1) | 9.4 (1.8) | 10.4 (1.9) * | 11.3 (2.0) * | <0.001 |
| SBP (mmHg) | 144 (24) | 139 (22) | 139 (21) | 146 (23) | 152 (28) * | <0.001 |
| DBP (mmHg) | 76 (14) | 72 (12) | 73 (12) | 77 (17) | 81 (14) * | <0.001 |
| Heart rate (bpm) | 69 (12) | 68 (11) | 68 (13) | 69 (12) | 71 (12) | 0.26 |
| Time-interval between CF-PWV measurements (years) | 4.2 (0.6) | 4.2 (0.5) | 4.3 (0.5) | 4.2 (0.6) | 4.2 (0.6) | 0.45 |
| Relative CF-PWV change (% per year) | +1.1 (-1.4 to +4.0) | -2.8 (-4.4 to -2.0) * | -0.2 (-0.8 to +0.4) | +2.1 (+1.5 to +3.0) * | +5.9 (+4.9 to +8.4) * | <0.001 |
| Relative MAP change (% per year) | -0.9 (-4.0 to +2.4) | -3.4 (-6.3 to +0.6) ‡ | -1.7 (-4.2 to +1.4) | +0.2 (-2.9 to +2.8) ‡ | +1.8 (-1.7 to +3.3) * | <0.001 |
| Relative heart rate change (% per year) | -0.9 (-3.4 to +1.1) | -1.4 (-3.8 to +0.7) | -0.8 (-2.9 to +1.8) | -1.0 (-3.6 to +0.6) | -0.5 (-2.6 to +2.6) | 0.045 |
| Laboratory variables b | | | | | | |
| Fasting glycemia (mmol/l) | 8.0 (2.8) | 7.8 (2.7) | 7.9 (2.9) | 8.2 (2.8) | 8.0 (2.8) | 0.73 |
| HbA1c (%) (mmol/mol) | 7.6 (1.3) | 7.4 (1.1) | 7.5 (1.3) | 7.7 (1.3) | 7.9 (1.5) ‡ | 0.008 |
| Triacylglycerol (mmol/l) | 1.8 (1.2) | 1.8 (1.2) | 1.9 (1.4) | 1.9 (1.2) | 1.9 (1.1) | 0.90 |
| HDL-cholesterol (mmol/l) | 1.1 (0.3) | 1.1 (0.3) | 1.1 (0.3) | 1.1 (0.3) | 1.1 (0.3) | 0.98 |
| LDL-cholesterol (mmol/l) | 2.6 (0.6) | 2.5 (0.6) | 2.6 (0.6) | 2.7 (0.7) | 2.6 (0.7) | 0.44 |
| eGFR (ml/min/1.73m²) | 72 (18) | 71 (17) | 73 (20) | 75 (17) | 70 (17) | 0.24 |
| Albuminuria (mg/24 h) | 16 (8–44) | 15 (8–39) | 17 (9–46) | 15 (9–33) | 21 (8–73) | 0.61 |

Outcomes incidence, absolute number (incidence rate per 1000 person-years of follow-up)
the lowest cumulative incidences of adverse outcomes in contrast to those who either had greater reductions or increases in CF-PWV.

Risks associated with changes in CF-PWV

Figure 3 presents graphically the adjusted risks associated with continuous relative CF-PWV changes modeled by Cox regressions with cubic splines to account for non-linear relationships. The lowest risk nadir point was estimated at -2.5% per year CF-PWV change, with significantly increased risks to the right of this nadir point (i.e., at greater increases in CF-PWV, beginning at +1.0%) for all-cause mortality, but without statistical significance for the other outcomes. To the left of the nadir point of CF-PWV changes (i.e., at greater reductions than −2.5%), there were slight non-significant excess risks for all-cause mortality and MACEs outcomes.

Table 2 outlines the adjusted risks associated with CF-PWV changes categorized into quartiles and also as stable/reduction/increase subgroups. Patients in the Q1 (greatest CF-PWV reductions) had significantly excess risks of all-cause and cardiovascular mortality, with HRs from 2.2 to 3.3; whereas those with greater CF-PWV increases had significantly excess risks of all outcomes, with adjusted HRs ranging from 1.9 to 3.4, in relation to the reference category who remained with stable CF-PWV. No evidence of interaction of CF-PWV changes with age or sex was found (all p-for-interaction values > 0.30), signifying that the risks associated with aortic stiffness changes were similar between older/younger individuals and men/women. Excluding the individuals who died within the first 2 years of follow-up also did not change any of the results, indicating that there was no reverse causality between CF-PWV changes and adverse outcomes.

Discussion

To the best of our knowledge, this is the first longitudinal study that evaluated the prognostic importance of aortic stiffness changes, assessed by its gold-standard CF-PWV measurement, in patients with type 2 diabetes. We demonstrated that a progressively increasing aortic stiffness over a 4-year period was associated with significantly higher risks of adverse cardiovascular outcomes and of all-cause mortality, independent of
classic risk factors and of other factors that might influence CF-PWV changes, such as changes in BP and heart rate and mean BP, HbA1c and lipid levels between the 2 CF-PWV measurements. This was observed both in analyses with continuous and categorical CF-PWV changes. Otherwise, we also evidenced that extreme CF-PWV
reductions, possibly greater than −2.5% to −3.0% per year, might be deleterious. However, this observation may be faced with caution, as this was evidenced only in analyses of categorical CF-PWV changes, but not supported in the spline analyses with continuous CF-PWV changes. Overall, our study suggested that monitoring aortic stiffness changes overtime, aiming to prevent its progression,
may be relevant to reduce cardiovascular morbidity and mortality burden in individuals with type 2 diabetes.

There were only 3 previous studies that evaluated changes in aortic stiffness as predictors of adverse outcomes, two of them in patients with end-stage renal failure undergoing dialysis [35, 36] and the other in patients with resistant hypertension [37]. They all agreed that preventing progression/increase in aortic stiffness was protective for cardiovascular outcomes [36, 37] and all-cause mortality [35, 37]; and none of them detected any signal of non-linear J-curve associations between CF-PWV changes and outcomes. Furthermore, most of the previous studies that evaluated the prognostic importance of a single CF-PWV measurement also reported linear dose-dependent associations between aortic stiffness and adverse outcomes [10], including those that evaluated exclusively patients with diabetes [11, 12, 38]. As far as we know, only one previous study [39], with 3034 elderly individuals without CVDs from the Atherosclerosis Risk in Communities (ARIC) cohort, reported a J-curve association between a single CF-PWV measurement and incident CVD, with hazard ratios of 1.8 and 2.0, respectively in the 4th and 1st quartile subgroups in relation to 2nd quartile subgroup. However, no spline analysis with continuous CF-PWV was performed to corroborate the possible non-linear association found in categorical analyses with quartile subgroups [39]. The reasons for these possible J-curve associations were unclear. In our study, patients in the 1st quartile subgroup of CF-PWV changes (i.e., with greatest CF-PWV reductions) were older, had longer diabetes duration and higher...
prevalence of arterial hypertension and, albeit they used more anti-hypertensive medications, they had higher BP levels and higher CF-PWV at the first measurement. Although we had adjusted all multivariable analyses for these covariates, some residual confounding may have still remained, which might have contributed to the increased risks observed in the subgroup with greatest CF-PWV reduction. Another possible explanation was some reverse causation between CF-PWV changes and adverse outcomes; that is, it may be the nearby event, particularly death, that might have driven the greater CF-PWV reduction, not the opposite. However, when we excluded from analysis those individuals who had any event during the first 2 years of follow-up, the 1st quartile subgroup still had higher risks than the reference 2nd quartile subgroup, not supporting the occurrence of reverse causation. Moreover, as pointed out before, there were no increased risks at the extreme of CF-PWV reduction in the Cox analyses with splines for any of the outcomes. Therefore, we believe that the observation that greater aortic stiffness reductions might be hazardous should be faced as hypothesis-generating and not as definite evidence, and it shall be examined in other larger cohorts of individuals with diabetes.

Aortic stiffness may be an integrate indicator not only of the effects of ageing and genetic background, but also of the cumulative damage of cardiovascular risk factors on the arterial wall overtime [7–9]. Current evidences [8, 15, 40] suggest that only part of aortic stiffness could be reduced through normalization of blood pressure by pharmacologic treatment; additional decrease of aortic stiffness would depend on long-term arterial remodeling, including reduction in collagen density and reorganization of arterial wall components. Particularly in diabetes, aortic stiffness may be accelerated by long-term hyperglycemia and formation of AGEs on the arterial wall, with loss of elastin and increased collagen cross-links [41]. Medications that are in current use for diabetes and hypertension may have potential anti-AGE or -RAGE effects. However, it is probable that the primary effects of antidiabetic, antihypertensive and statin drugs are more important than their pleiotropic secondary AGE or RAGE opposing effects [25]. The rationale of maintaining low stable aortic stiffness shall still be based on long-term optimal metabolic and BP control by pharmacological and non-pharmacological therapies [7, 8, 19, 20, 22, 23].

This study has limitations that shall be noted. First, this is an observational cohort study on the prognostic value of changes in CF-PWV and, as such, no direct inference can be made regarding cause-and-effect relationships or physiopathological mechanisms. Second, as already pointed out, as in any cohort study, some residual confounding cannot be ruled out. Third, as in any study with serial measurements of a biological variable, the possibility of influence of the ‘regression-to-the-mean’ phenomenon and its associated ‘regression
The overall ‘regression-to-the mean’ effect in these two CF-PWV measurements was small. Finally, our cohort was initiated in 2004, and the use of the new antidiabetic medications with cardiovascular protection effects was very rare. Hence, our findings might not be generalized to individuals with type 2 diabetes using these new drugs. Otherwise, currently, most people with diabetes are still using the traditional drug treatments with metformin, sulphonylureas and insulin, as in our cohort. Furthermore, this cohort enrolled mainly middle-aged to elderly individuals with long-standing type 2 diabetes followed-up in a tertiary-care university hospital. Hence, our results might also not be generalized to younger individuals with recent onset diabetes or to less severe ones at primary care management. On the other hand, strengths of this study include a well-characterized cohort of individuals with type 2 diabetes actively followed-up under a standardized management, and the multivariable statistical adjustment for several potential confounders that may have affected CF-PWV changes [18].

Conclusions
This prospective study in individuals with type 2 diabetes provides evidence that changes in aortic stiffness, assessed by 2 CF-PWV measurements over a 4-year interval, are independent risk markers for adverse cardiovascular outcomes and mortality. Patients who had increases in CF-PWV had significantly worse cardiovascular and mortality prognoses than those who remained with stable or moderately-reduced CF-PWV, although extreme CF-PWV reductions might be deleterious. Therefore, depending on confirmation from larger studies, monitoring aortic stiffness changes by serial CF-PWV assessments, aiming to prevent its progression, may be relevant for reducing cardiovascular and mortality risks in patients with type 2 diabetes. Whether a therapeutic strategy based on serial CF-PWV measurements may be recommended in the clinical management of diabetes, this shall be examined in future studies.

Abbreviations
AGES: Advanced glycation end-products; BMI: Body mass index; BP: Blood pressure; CF-PWV: Carotid-femoral pulse wave velocity; CI: Confidence interval; CVEs: Cardiovascular events; DBP: Diastolic blood pressure; HbA1c: Glycated hemoglobin; HR: Hazard ratio; MACEs: Major adverse cardiovascular events; MAP: Mean arterial pressure; RAGE: Advanced glycation end-products receptor; SBP: Systolic blood pressure.

Acknowledgements
Not applicable.

Author contributions
NCL, CRLC and GFS conceived and designed the study, followed-up the patients and obtained the data. CRLC drafted the manuscript. GFS analyzed the data and is the guarantor. All authors helped interpret the results and reviewed the manuscript. GFS had full access to all of the data and takes responsibility for the integrity of the data and the accuracy of data analysis.

Funding
This study was supported by grants 304069/2019-1 and 303492/2019-8 from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil) and by grants E-26/202.807/2017 and E-26/202.535/2019 from the Fundação Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ, Brazil). The sponsors have no role in study design, data collection and analysis, results interpretation or in preparation, review and approval of the manuscript.

Availability of data and materials
The Rio de Janeiro Type 2 Diabetes Cohort Study is an on-going study, and its dataset is not publicly available due to individual privacy of the participants. However, it may be available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study was approved by the Research Ethics Committee of School of Medicine and University Hospital, Federal University of Rio de Janeiro (number 124/2004), and all participants gave written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 8 February 2022   Accepted: 22 April 2022
Published online: 14 May 2022

References
1. Henry RM, Kostenze PJ, Spijkerman AM, Dekker JM, Nijpels G, Heine RJ, et al. Hoorn Study. Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation. 2003;107:2089–95.
2. Brenner SB, Chirinos JA. Arterial stiffness in diabetes mellitus. Atherosclerosis. 2015; 238:370–9.
3. Chirinos JA, Segers P, Gillebert TC, De Buyzere ML, Van Daele CM, Khan ZA, et al. Asklepios investigators. Central pulse pressure and its hemodynamic determinants in middle-aged adults with impaired fasting glucose and diabetes: the Asklepios study. Diabetes Care. 2013;36:2359–63.
4. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al., Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.
5. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.
6. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjornsdottir S, et al. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015;373:1720–32.
7. Stenhouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia. 2008;51:527–39.
8. Boutouyrie P, Chowienczyk P, Humphrey JD, Mitchell GF. Arterial stiffness and cardiovascular risk in hypertension. Circ Res. 2021;128:864–86.
9. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–27.

Acknowledgements
Not applicable.
10. Ben-Shlomo Y, Spears M, Bousted C, May M, Anderson SG, Benjamin EJ, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63:636–46.

11. Cardoso CR, Ferreira MT, Leite NC, Salles GF. Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio de Janeiro type 2 diabetes cohort study. Diabetes Care. 2013;36:3772–8.

12. Wijkmann M, Länne T, Ostgren CJ, Nyström FH. Aortic pulse wave velocity predicts incident cardiovascular events in patients with type 2 diabetes treated in primary care. J Diabetes Complicat. 2016;30:1223–8.

13. Benetos A, Adamopoulos C, Bureau JM, Temmari M, Labat C, Bean K, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation. 2002;105:1202–7.

14. Wildman RP, Farhat GN, Patel AS, Mackey RH, Brockwell S, Thompson T, Sutton-Tyrrell K. Weight change is associated with change in arterial stiffness among healthy young adults. Hypertension. 2005;45:187–92.

15. Ait-Oufella H, Collin C, Bozec E, Laloux B, Ong KT, Dutouil C, et al. Long-term reduction in aortic stiffness: a 5.3-year follow-up in routine clinical practice. J Hypertens. 2010;28:2336–41.

16. Birru MS, Matthews KA, Thurston RC, Brooks MM, Ibrahim S, Barinas-Mitchell E, et al. SWAN heart study. African-American ethnicity and cardiovascular risk factors are related to aortic pulse-wave velocity progression. Ann J Hypertens. 2011;24:809–15.

17. Al Ghatri M, Strait JB, Morell CH, Canepa M, Wright J, Elango P, et al. Longitudinal trajectories of arterial stiffness and the role of blood pressure: the Baltimore longitudinal study of aging. Hypertension. 2013;62:934–41.

18. Ferreira MT, Leite NC, Cardoso CR, Salles GF. Correlates of aortic stiffness progression in patients with type 2 diabetes: importance of glycemic control: the Rio de Janeiro type 2 diabetes cohort study. Diabetes Care. 2015;38:989–94.

19. Petersen KS, Blanch N, Keogh JB, Clifton PM. Effect of weight loss on pulse wave velocity: systematic review and meta-analysis. Arterioscler Thromb Vasc Biol. 2015;35:243–52.

20. Ashor AW, Lara J, Servio M, Celis-Morales C, Mathers JC. Effects of exercise modalities on arterial stiffness and wave reflection: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e110034.

21. Kalaridde J, Smith A, DeAngelis L, Mirenda V, Kandra A, Botha J, et al.; SWAN Heart Study. African-American ethnicity and cardiovascular risk factors are related to aortic pulse-wave velocity progression. Ann J Hypertens. 2011;24:809–15.

22. Udupa S, Wirunsawanya K, Jaruvongsanich V, Sanguankeo A. Effects of statin therapy on arterial stiffness: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2017;227:338–41.

23. Batzias K, Antonopoulos AS, Oikonomou E, Siasos G, Bletsa E, Stathopoulou G, et al. Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis. J Diabetes Res. 2018;2018:1232583.

24. Kass DA, Shapiro EP, Kawaguchi MA, Capriotti AR, Scuteri A, deGroof RC, et al. Cross-linking of glycated collagen in the pathogenesis of arterial stiffness for adverse cardiovascular outcomes and mortality in patients with resistant hypertension: a prospective cohort study. Hypertension. 2022;79:447–56.

25. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002;106:2085–90.

26. Kim ED, Ballew SH, Tanaka H, Heiss G, Coresh J, Matsushita K. Short-term prognostic impact of arterial stiffness in older adults without prevalent cardiovascular disease. Hypertension. 2019;74:1373–82.

27. Laurent S, Boutoury V. Vascular mechanism collaboration. Dose-dependent arterial distensibility and inward remodeling after olmesartan in hypertensive with metabolic syndrome. Hypertension. 2014;64:709–16.

28. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. 2003;21:3–12.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.